Rejuvenate Bio appoints Deborah Ascheim as its first chief medical officer

Rejuvenate Bio

Rejuvenate Bio named cardiologist Deborah Ascheim as its first chief medical officer to lead clinical and regulatory work for its gene therapies for age-related diseases. Dr. Ascheim brings over 30 years as a physician and clinical investigator, including two decades in academia as a heart failure cardiologist and director of national and international clinical trials for disruptive therapeutics including gene therapies.

• Dr. Ascheim is a heart failure cardiologist with two decades in academic medicine leading clinical trials.
• Previously CMO of StrideBio, where she led strategy, design and execution of gene therapy clinical trials.
• Was Professor of Health Policy and Medicine at Icahn School of Medicine at Mount Sinai for nearly a decade.
• Over 30 years experience as physician, clinical investigator and director of trials for novel therapeutic innovations.